Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page
- Check6 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedFooter now displays Revision: v3.3.4 and the previous Revision: v3.3.3 has been removed.SummaryDifference0.0%

- Check49 days agoChange DetectedAdded and updated the Locations sections to include California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington, and Alberta/Ontario; removed the prior state-location entries and the HHS Vulnerability Disclosure link.SummaryDifference0.6%

- Check71 days agoChange DetectedPublications section added: Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. This update does not alter the study design, eligibility criteria, endpoints, or enrollment.SummaryDifference0.0%

- Check78 days agoChange DetectedThe Publications section now states entries are automatically filled from PubMed and may not all pertain to the study, and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check85 days agoChange DetectedRemoved the government funding/status notice that warned about potential delays and operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.